PROTAC MOLECULES TARGETING FOXP3 AND USES THEREOF
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Feb 13, 2025
app pub date -
Jan 5, 2023
filing date -
Jan 5, 2023
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
A bi-functional, proteolysis-targeting chimera (PROTAC) agent is provided for the modulation of transcriptional factor FOXP3 and associated regulatory T cells. The agent contains an inhibitory peptide of FOXP3 covalently bound through a linker to a ubiquitin ligase binding moiety. The agent binds FOXP3 and recruits an E3 ubiquitin ligase, and thereby bringing FOXP3 in proximity to the E3 ubiquitin ligase for ubiquitination and degradation of the FOXP3. Methods of preparation and use of the agent are also provided.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully